Are you saying somebody can read this IP and get clues and come up with a different, non-infringing way of making biosimilar?
Clearly, there’s a tradeoff here. Patenting a manufacturing process may have value, but no company wants to show its competitors any more that it has to.
“The notion that there’s a Chinese Wall between sell-side analysts and investment bankers may be the second-biggest piece of BS ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.